Treatment of spinocerebellar ataxia with buspirone

Mitra Assadi, Joseph V. Campellone, Christopher G. Janson, J. Jon Veloski, Robert J. Schwartzman, Paola Leone

Research output: Contribution to journalArticlepeer-review

25 Scopus citations


Preliminary data suggest potential benefit of 5-HT receptor agonists in the treatment of ataxias. We studied the effects of buspirone in a cohort of twenty patients with spinocerebellar ataxia (SCA). Twenty patients were treated in this double-blind, placebo controlled, cross-over trial with either buspirone HCl 30 mg twice daily or placebo for 3 months. Buspirone was not shown to be superior to placebo in the treatment of patients with SCA.

Original languageEnglish (US)
Pages (from-to)143-146
Number of pages4
JournalJournal of the Neurological Sciences
Issue number1-2
StatePublished - Sep 15 2007

All Science Journal Classification (ASJC) codes

  • Neurology
  • Clinical Neurology


Dive into the research topics of 'Treatment of spinocerebellar ataxia with buspirone'. Together they form a unique fingerprint.

Cite this